CIMB Group appoints Syed Zaid as chairman following Nasir's retirement
KUALA LUMPUR: CIMB Group Holdings Bhd has redesignated Datuk Syed Zaid Syed Jaffar Albar as its independent and non-executive chairman, effective July 20, 2025.
Syed Zaid, 71, succeeds Tan Sri Mohd Nasir Ahmad, who retired from the board on July 19.
The board of CIMB Group will comprise nine members effective July 20. Syed Zaid will serve as the independent and non-executive chairman, with Muhammad Novan Amirudin as group chief executive officer and executive director, and Didi Syafruddin Yahya as senior independent director.
Other members include Datuk Lee Kok Kwan and Tengku Datuk Seri Azmil Zahruddin Raja Abdul Aziz as non-independent directors, along with Shulamite N K Khoo, Ho Yuet Mee, Datin Azlina Mahmad, and Lyn Therese McGrath as independent directors.
Meanwhile, CIMB Bank Bhd has signed a collaboration agreement with Pharmaniaga Logistics Sdn Bhd, a wholly owned subsidiary of Pharmaniaga Bhd, to enhance supply chain financing and improve payment flexibility for SMEs in the healthcare sector.
The bank said the partnership aims to provide greater financial flexibility to clinics, pharmacies and medical buyers across the sector.
Under the collaboration, CIMB and Pharmaniaga will offer enhanced payment flexibility to private clinics and independent pharmacies via the CIMB SME BusinessCard.
CIMB said businesses can enjoy up to 50 days of extended credit and earn a 0.5% unlimited cash rebate on all Pharmaniaga purchases, helping improve cash flow and optimise working capital.
CIMB Group co-chief executive officer of group commercial and transaction banking, Lawrence Loh, said the partnership with Pharmaniaga aims to provide practical and value-added financing support for healthcare SMEs.
He said these businesses are essential to Malaysia's healthcare ecosystem, and equipping them with the right financial tools is vital to enhancing their resilience and ability to deliver quality care.
'By offering extended credit terms and early settlement incentives, we help clinics, pharmacies, and medical buyers better manage cash flow, reduce operational strain, while enhancing the quality of care they provide,' he said.
Meanwhile, Pharmaniaga managing director Zulkifli Jafar said: 'We encourage more clinics, pharmacies and healthcare SMEs leverage on this facility to ease daily operational and financial challenges.'
'By offering greater payment flexibility and tailored financing options, we aim to empower our partners to grow sustainably while ensuring continuous access to a broad range of pharmaceutical products to serve their clients with confidence,' he added.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
5 hours ago
- New Straits Times
Tariff uncertainties to pose zero direct impact on CIMB's FY2026: Group CEO
KUALA LUMPUR: CIMB Group Holdings Bhd says the prevailing uncertainty surrounding global tariff policies will not have a direct impact on its financial performance for the financial year ending 2026 (FY2026). This will be due to the group's diversified income strategy and sustainable operational efficiency. CIMB Group chief executive officer Novan Amirudin said while global tariffs could potentially weigh on regional economic growth, the impact on the bank remains limited and largely depends on how the additional costs are distributed along the supply chain. "It depends on whether the costs are borne by producers in Asean, consumers in the United States, or absorbed by governments through incentives and supportive policies," he said during a fireside chat held in conjunction with CIMB's Asean Media Day today. He added that if restrictions on exports from China to the United States prompt manufacturers to relocate to Asean, any resulting oversupply could put pressure on local producers. "This situation could slow regional growth and indirectly affect the financial sector, as loan growth is closely tied to economic activity," he explained. Nevertheless, he said CIMB does not rely solely on interest income but has also strengthened its non-interest income streams. "About 30 per cent of the group's income comes from non-interest sources, including transaction fees, foreign exchange, payment solutions and advisory services. "These initiatives are aligned with our Forward 30 strategy, which emphasises revenue stream diversification," he said. On the recent Overnight Policy Rate (OPR) cut by Bank Negara Malaysia, he said the move impacts the lending rates offered to customers. CIMB also adjusted its deposit rates, such as fixed deposits, which are now at lower levels. "A lower OPR typically reduces funding costs. Therefore, the net impact on the bank depends on how much lending and deposit rates are adjusted. "If we are able to reduce deposit rates further, we can still maintain our net interest margins," he said.
BusinessToday
9 hours ago
- BusinessToday
Refuelling Sarawak's Growth
Sarawak is fast positioning itself as Malaysia's clean energy powerhouse with bold plans to quadruple power generation to 15GW by 2035. A recent field trip by CIMB Research to the state revealed that major shifts are underway — not just in energy, but also in infrastructure, digitalisation, and industrial expansion — aligned with Sarawak's Post COVID-19 Development Strategy 2030 (PCDS 2030). CIMB analysts identified key beneficiaries of the state's growth plans ahead of its next election, due by April 2027. Infrastructure giants like Gamuda and IJM, as well as Sarawak-based names Cahya Mata, Ibraco, Solarvest, CCK, and Supreme Consolidated, are all poised to ride the wave of development. A Green Leap Forward Sarawak's clean energy agenda is being driven by a pivot away from mega dams toward cascading hydro, floating solar, pumped hydro, and integrated hydro-solar projects. Its landmark hydrogen programmes, H2ornbill and H2biscus, aim to generate over 240,000 tonnes of hydrogen annually by 2029, with exports targeted at Japan and South Korea. The state's strategic shift includes deprioritising coal and rare earth mining, while doubling down on green cement, silica-based solar glass, and biofuels. Major infrastructure upgrades, including a RM4 billion water grid, are also underway to support these ambitions. Industrial Parks and Transport Mega-Projects Sarawak plans to construct 10 new industrial parks and 6 agro-parks, alongside the expansion of existing industrial hubs such as Samalaju Industrial Park (SIP) and Petchem Industrial Park in Kidurong. With strong demand, only 12% of land at SIP remains available, despite already attracting RM57 billion in investments. Infrastructure development is also intensifying. The state is pursuing transformative projects such as a new airport and deep seaport in Kuching, the Lawas Airport and port complex, and major road, water, and utility upgrades. The Kuching Urban Transportation System (KUTS), featuring hydrogen-powered Autonomous Rapid Transit (ART), is a headline initiative under Sarawak Metro, expected to begin operations in 2028. Phase 1 of KUTS, valued at over RM6 billion, will span 70km across 28 stations. Hydrogen fuel cell vehicles will be supported by a purpose-built depot in Rembus, and a RM122 million contract for 55 feeder buses has already been awarded. Strategic Investment and Clean Energy Partnerships Sarawak's investment agency, InvestSarawak, operating under MINTRED, has been actively securing green investments. A notable development was the signing of an MoU with China's CRE International in 2024 to explore USD1.5 billion (RM6.4 billion) worth of solar, wind, and energy storage projects with a capacity target of 2GW. MINTRED has also launched ENBASE, a digital platform to support entrepreneurial development, and is spearheading efforts to attract investments in semiconductors, medical devices, and green hydrogen. Deputy Premier Datuk Amar Awang Tengah Ali Hassan recently led a trade mission to France, engaging with private equity firm Ardian on high-tech sector opportunities. SCORE and the Corridor Vision Driving long-term industrialisation is the Sarawak Corridor of Renewable Energy (SCORE), which spans 80% of the state. Managed by RECODA, SCORE has already secured RM127 billion in approved investments across 464 projects, mainly in energy-intensive sectors. RECODA also oversees over 250 infrastructure projects and administers social programmes focused on poverty reduction, workforce upskilling, and rural development. Its regional development arms — URDA, HDA, and NRDA — have tailored master plans to ensure inclusive and area-specific progress. Election-Led Re-Rating Opportunities With the next Sarawak state election expected before April 2027, CIMB foresees a potential re-rating of Sarawak-linked stocks, particularly in infrastructure and consumer sectors. Companies like Gamuda and IJM are favoured for their involvement in road and public transport contracts, while Cahya Mata, Ibraco, Solarvest, CCK, and Supreme stand to benefit from surging state-level economic activity. However, risks remain. These include funding and talent constraints, rising competition from foreign contractors, and the still-limited participation of public-listed players in large hydrogen or hydroelectric ventures. Looking ahead, Sarawak's clear policy direction reinforces the state's vision to become a high-income and developed state by 2030. With a record-high RM15.8 billion budget for 2025 and 70% allocated to development, the transformation is not just aspirational — it's already underway. Related
New Straits Times
11 hours ago
- New Straits Times
Pharmaniaga shares soar past 45pc, volume hits two-year high
KUALA LUMPUR: Shares of Pharmaniaga Bhd soared more than 45 per cent in active trade, as buying momentum lifted trading volume to levels not seen in over two years. At 11.54am, the stock was up six sen or 38.71 per cent at 21.5 sen, with 51 million shares changing hands, its busiest day since April 20, 2023. It was the second most actively traded counter at the time. The stock opened 9.68 per cent higher at 17 sen and rose as much as 22.5 sen, up 45.16 per cent from its previous close of 15.5 sen. There have been no fresh corporate announcements aside from the renounceable rights issue of up to 3.52 billion shares announced earlier this month. On July 1, the counter went ex-rights, triggering a technical price adjustment from 23.5 sen on June 30 to 16 sen. Until today's rally, the stock had been trading between 14 sen and 16.5 sen. At 22 sen, it is now edging back toward its pre-rights issue level above 20 sen. Pharmaniaga, once weighed down by a RM552.3 million impairment from unsold Covid-19 vaccines, slipped into Practice Note 17 (PN17) status in February 2023. But the company has since returned to profitability in the financial year ended Dec 31, 2024 (FY24) and expects to stay in the black in FY25. The group is eyeing revenue of RM4 billion this year, up from RM3.8 billion in FY24, a level it last crossed in FY21. Its managing director Zulkifli Jafar has said the company aims to exit PN17 status by the end of this year or early 2026. Pharmaniaga is majority-owned by Boustead Holdings Bhd, which in turn is controlled by Lembaga Tabung Angkatan Tentera (LTAT). According to the latest annual report, LTAT holds a direct 44.47 per cent stake in the company.
